IP Library › Granted Patent US 10,851,066
Granted Patent B2
US 10,851,066 · App. 16/888,040 · Granted Dec 1, 2020

2-arylbenzimidazoles as PPARGC1A activators for treating neurodegenerative diseases

Inventors: Samuel D. Banister (Castle Hill, AU); Edgar Engleman (Redwood City, CA); Khoa D. Nguyen (Redwood City, CA); Mark Smith (Redwood City, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
C07D235/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,851,066
App. No.
16/888,040
Granted
Dec 1, 2020
Kind
B2
Abstract

The compound 2-(3-tert-Butylphenyl)-4,6-difluoro-1H-benzo[d]imidazole and its use are disclosed: The compound activates Ppargc1a and, as a consequence, is useful for treating neuroinflammation and for treating a variety of neurodegenerative diseases.

Claims (5)

1. A compound of formula:

2. A compound according to claim 1 , in free base form.

3. A compound according to claim 1 , in the form of a pharmaceutically acceptable salt.

4. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 2 .

5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 3 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2020
From: BANISTER, SAMUEL D.; ENGLEMAN, EDGAR; NGUYEN, KHOA D.; SMITH, MARK
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 052806/0236 →
Continuity (3)
Continuation PCTUS2019045229 · Aug 6, 2019
Provisional Application 62714962 · Aug 6, 2018
Related Publication 20200299244A1 · Sep 24, 2020
Cited By (2)
US 12,195,432 US 12,678,424